Immune-Checkpoint Blockade Therapy in Lymphoma

被引：35

作者：

Kuzume, Ayumi ^{[1
,2
]}

Chi, SungGi ^{[1
]}

Yamauchi, Nobuhiko ^{[1
]}

Minami, Yosuke ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Hematol, Kashiwa, Chiba 2778577, Japan

[2] Kameda Med Ctr, Dept Hematol, Kamogawa 2968602, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 15期

关键词：

hematologic malignancies; immunotherapy; programmed cell-death protein 1 (PD-1); B-CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; PROGRAMMED DEATH-1 BLOCKADE; REGULATORY T-CELLS; HIGH RESPONSE RATE; FOLLICULAR LYMPHOMA; BRENTUXIMAB VEDOTIN; PD-1; BLOCKADE; PHASE-II; TUMOR MICROENVIRONMENT;

D O I：

10.3390/ijms21155456

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective.

引用

页码：1 / 15

页数：15

共 100 条

[1] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[2] Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells [J].

Andorsky, David J. ;

Yamada, Reiko E. ;

Said, Jonathan ;

Pinkus, Geraldine S. ;

Betting, David J. ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4232-4244

[3] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study [J].

Ansell, Stephen M. ;

Minnema, Monique C. ;

Johnson, Peter ;

Timmerman, John M. ;

Armand, Philippe ;

Shipp, Margaret A. ;

Rodig, Scott J. ;

Ligon, Azra H. ;

Roemer, Margaretha G. M. ;

Reddy, Nishitha ;

Cohen, Jonathon B. ;

Assouline, Sarit ;

Poon, Michelle ;

Sharma, Manish ;

Kato, Kazunobu ;

Samakoglu, Selda ;

Sumbul, Anne ;

Grigg, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) :481-+

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[6] Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma [J].

Armand, Philippe ;

Rodig, Scott ;

Melnichenko, Vladimir ;

Thieblemont, Catherine ;

Bouabdallah, Kamal ;

Tumyan, Gayane ;

Ozcan, Muhit ;

Portino, Sergio ;

Fogliatto, Laura ;

Caballero, Maria D. ;

Walewski, Jan ;

Gulbas, Zafer ;

Ribrag, Vincent ;

Christian, Beth ;

Perini, Guilherme Fleury ;

Salles, Gilles ;

Svoboda, Jakub ;

Zain, Jasmine ;

Patel, Sanjay ;

Chen, Pei-Hsuan ;

Ligon, Azra H. ;

Ouyang, Jing ;

Neuberg, Donna ;

Redd, Robert ;

Chatterjee, Arkendu ;

Balakumaran, Arun ;

Orlowski, Robert ;

Shipp, Margaret ;

Zinzani, Pier Luigi .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) :3291-+

[7] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].

Armand, Philippe ;

Shipp, Margaret A. ;

Ribrag, Vincent ;

Michot, Jean-Marie ;

Zinzani, Pier Luigi ;

Kuruvilla, John ;

Snyder, Ellen S. ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Rose, Shelonitda ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+

[8] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[9] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[10] PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [J].

Bi, Xi-wen ;

Wang, Hua ;

Zhang, Wen-wen ;

Wang, Jing-hua ;

Liu, Wen-jian ;

Xia, Zhong-jun ;

Huang, Hui-qiang ;

Jiang, Wen-qi ;

Zhang, Yu-jing ;

Wang, Liang .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

← 1 2 3 4 5 6 7 8 9 10 →